Related Experiment Video
Updated: Jan 18, 2026

A Reporter Assay to Analyze Intronic microRNA Maturation in Mammalian Cells
Published on: June 16, 2022
Linc01271 promotes lipid synthesis and MASLD/MASH progression via miR-149-3p/RAB35 axis
Zhaoqing Yin1,2, Caibin Yue3,4, Zhipeng Li1,2
1Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, China.
Abstract:
Metabolic associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by hepatocellular injury, inflammation, and fibrosis. Despite advances in understanding its pathophysiology, the molecular mechanisms driving MASH progression remain unclear. This study investigates the role of long non-coding RNA Linc01271 in MASLD/MASH pathogenesis, ant its involvement in the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR signaling pathway. Transcriptome sequencing and RT-qPCR revealed significant upregulation of Linc01271 in MASH tissues, which correlated with lipid accumulation and inflammatory responses. Knockdown of Linc01271 in THLE-2 cells reduced lipid droplet formation, triglyceride and cholesterol levels, and the expression of lipid metabolism-related genes (CD36, ACC1, FASN) and pro-inflammatory cytokines (IL-6, IL-8, TGF-β1). Conversely, Linc01271 overexpression had the opposite effect. Dual-luciferase reporter assays confirmed Linc01271's interaction with miR-149-3p, which regulates RAB35, a downstream target of miR-149-3p. Knockdown of Linc01271 in mice attenuated MASH progression, reducing body weight, liver weight, blood glucose levels, and liver injury markers. These findings demonstrate that Linc01271 promotes lipid synthesis and inflammatory responses through the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR pathway, highlighting its potential as a therapeutic target for MASLD/MASH. Further research is warranted to develop therapeutic agents targeting Linc01271 for clinical applications.
Insights
Long non-coding RNA Linc01271 promotes metabolic associated steatohepatitis (MASH) by increasing lipid synthesis and inflammation. Targeting Linc01271 may offer a new therapeutic strategy for MASH.
Area of Science:
- Hepatology
- Molecular Biology
- Genetics
Background:
- Metabolic associated steatohepatitis (MASH) is a severe liver condition linked to metabolic dysfunction.
- The precise molecular drivers of MASH progression are not fully understood.
- Identifying novel molecular targets is crucial for developing effective MASH therapies.
Purpose of the Study:
- To investigate the role of long non-coding RNA Linc01271 in the pathogenesis of MASH.
- To elucidate the molecular mechanisms involving the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR pathway in MASH.
- To assess Linc01271 as a potential therapeutic target for MASH.
Main Methods:
- Transcriptome sequencing and RT-qPCR to analyze Linc01271 expression in MASH tissues.
- In vitro experiments using THLE-2 cells to assess the effects of Linc01271 knockdown or overexpression on lipid metabolism and inflammation.
- Dual-luciferase reporter assays to confirm interactions between Linc01271 and miR-149-3p.
- In vivo studies in mice to evaluate the impact of Linc01271 knockdown on MASH progression.
Main Results:
- Linc01271 was significantly upregulated in MASH tissues, correlating with increased lipid accumulation and inflammation.
- Linc01271 knockdown in cells reduced lipid synthesis and pro-inflammatory cytokine expression.
- Linc01271 was confirmed to interact with miR-149-3p, influencing the regulation of RAB35.
- Linc01271 knockdown in mice ameliorated MASH, reducing liver injury and metabolic dysfunction markers.
Conclusions:
- Linc01271 promotes MASH by enhancing lipid synthesis and inflammatory responses via the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR pathway.
- Linc01271 represents a promising therapeutic target for MASLD/MASH.
- Further investigation is needed to develop Linc01271-targeted therapies for clinical application.
Related Concept Videos
MicroRNAs
MicroRNAs
Lipid Catabolism
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades

